Severe liver fibrosis caused by Schistosoma mansoni: management and treatment with a transjugular intrahepatic portosystemic shunt

Richter, Joachim; Bode, Johannes G.; Blondin, D.; Kircheis, G.; Kubitz, Ralf; Holtfreter, Martha C.; Müller-Stöver, Irmela; Breuer, Matthias; Hüttig, Falk; Antoch, Gerald; Häussinger, Dieter

doi:10.1016/s1473-3099(15)70009-5

Cited by 42 publications

(28 citation statements)

References 80 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients with liver fibrosis associated with hepatitis B virus (HBV) or HCV infection treated with antiviral therapies have shown fibrosis regression and histological improvements even in cases of cirrhosis (17)(18)(19). Liver fibrosis triggered by schistosomiasis, one of the most common causes of liver fibrosis worldwide, is also thought to regress upon treatment of infection (20,21). Common experimental rodent models for liver fibrosis include administration of a hepatotoxin (e.g., carbon tetrachloride [CCl 4 ]) to induce acute hepatocellular injury or bile duct ligation (BDL) to induce cholestasis, resulting in pericentral or periportal liver fibrosis, respectively.…”

Section: Reversibility Of Organ Fibrosismentioning

confidence: 99%

Resolution of organ fibrosis

Jun

Lau

2018

Journal of Clinical Investigation

269

212

View full text Add to dashboard Cite

Fibrosis is the excessive accumulation of extracellular matrix that often occurs as a wound healing response to repeated or chronic tissue injury, and may lead to the disruption of organ architecture and loss of function. Although fibrosis was previously thought to be irreversible, recent evidence indicates that certain circumstances permit the resolution of fibrosis when the underlying causes of injury are eradicated. The mechanism of fibrosis resolution encompasses degradation of the fibrotic extracellular matrix as well as elimination of fibrogenic myofibroblasts through their adaptation of various cell fates, including apoptosis, senescence, dedifferentiation, and reprogramming. In this Review, we discuss the present knowledge and gaps in our understanding of how matrix degradation is regulated and how myofibroblast cell fates can be manipulated, areas that may identify potential therapeutic approaches for fibrosis.

show abstract

Section: Reversibility Of Organ Fibrosismentioning

confidence: 99%

Resolution of organ fibrosis

Jun

Lau

2018

Journal of Clinical Investigation

269

212

View full text Add to dashboard Cite

show abstract

“…If only school age children ((46.4%; 5–14 years of age) were targeted the cost would drop to 9.61 million USD. Affected populations would benefit from other effects of praziquantel on other complications and sequeleae of schistosomiasis, including renal impairment, increased transmission of HIV, HBV, HTLV and other STDs sterility, complicated pregnancy, bleeding from esophageal varices, to mention just a few (35,36,37). …”

Section: Resultsmentioning

confidence: 99%

Halting Schistosoma haematobium - Associated Bladder Cancer

2017

Self Cite

View full text Add to dashboard Cite

Background At present schistosomiasis is endemic in 78 countries affecting more than 260 million people. Schistosomiasis haematobia alone affects more than 112 millions. Material and Methods We performed a computerized search of Pubmed database with keywords: bladder cancer cost and schistosomiasis mass treatment. Results Bladder cancer is an important sequelae of this infection. In low-resource countries, where this disease is endemic, individuals inflicted with bladder cancer have very limited access to treatment and death is most probably certain. Conclusion Mass treatment with praziquantel is an easy, safe and inexpensive treatment that could save the lives of thousands and reduce the morbidity of millions.

show abstract

“…graphy using acoustic radiation force impulse (ARFI) detects an increased stiffness of the echogenic portal areas and of those in the spleen [81]. In well equipped hospitals, endosonography [101,102], computed tomography, and especially magnetic resonance imaging may contribute to further assessment of liver fibrosis and the associated hemodynamic abnormalities [81]. The use of contrast-enhanced ultrasound in patients with schistosomiasis has only been performed in specialized centers [103,104].…”

Section: Descriptive Ultrasound Field Methods To Assess Liver Fibrosismentioning

confidence: 99%

“…Although estimates are not available, schistosomiasis must still be considered to be the most frequent cause of liver fibrosis worldwide [80]. Schistosomal liver fibrosis differs in almost all respects from non-cirrhotic portal hypertension, a disease reported from India, where human schistosomiasis fortunately is not endemic [81]. Other causes of portal hypertension have to be considered [82 -84].…”

Section: Hepatosplenic Schistosomiasismentioning

confidence: 99%

Ultrasound assessment of schistosomiasis

et al. 2016

View full text Add to dashboard Cite

In 2000, the World Health Organization (WHO) issued an ultrasound field protocol for assessing the morbidity due to Schistosoma (S.) haematobium and S. mansoni. The experience with this classification has recently been reviewed systematically. The WHO protocol was well accepted worldwide. Here we review the use of ultrasound to assess the morbidity due to schistosomiasis with emphasis on easy, quick, and reproducible ways that can be used in the field. Findings obtained with high-end ultrasound scanners in the hospital setting that might eventually have applications in the field are also described.

show abstract

Severe liver fibrosis caused by Schistosoma mansoni: management and treatment with a transjugular intrahepatic portosystemic shunt

Cited by 42 publications

References 80 publications

Resolution of organ fibrosis

Resolution of organ fibrosis

Halting Schistosoma haematobium - Associated Bladder Cancer

Ultrasound assessment of schistosomiasis

Contact Info

Product

Resources

About